DGAP-News: FIDURA Private Equity Fonds / Key word(s): Sales Result
FIDURA Private Equity Funds: Successful sale of portfolio company m2p-labs GmbH to Beckman Coulter Life Sciences
Lead investor FIDURA announces the acquisition of bioprocessing specialist m2p-labs by Beckman Coulter Life Sciences
Founded in 2005, m2p-labs is a leading global manufacturer of microbioreactors.
"Innovation defines our future," said Greg Milosevich, President, Beckman Coulter Life Sciences. "m2p-labs core product line complements our existing liquid handling and laboratory automation business. It provides new opportunities for our collective team to develop and enhance time-saving solutions for cell line development and process development workflows."
We are pleased to have found in Beckman Coulter Life Sciences the ideal strategic partner to further realize the great potential of the m2p product portfolio. Our buy-and-build strategy has thus been implemented extremely successfully, adds Klaus Ragotzky, Managing Director of lead investor FIDURA Private Equity Fonds.
Marco Winzer, Partner of High-Tech Gründerfonds and Dr. Christoph Petry, CEO of m2p-labs GmbH, add: "Our consortium of investors was for many years an excellent financial partner and sparring partner for the m2p team. This helped enable the company to realise rapid growth as a market leader in bioprocessing and develop unique microfluidic technology while optimizing and improving internal processes."
About Beckman Coulter Life Sciences
FIDURA is a German group of independent Private Equity Funds, investing in growth-oriented and innovative mid-sized companies based primarily in German-speaking countries. The fund management team provides companies with personal networks and own entrepreneurial wealth of experience.
For more information visit www.fidura.de
13.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.